Comparative Trial of Serotonin Antagonists in the Management of Migraine

Overview

Journal Br Med J

Specialty General Medicine

Date 1970 May 9

PMID 4393372

Citations 13

Authors

J W Lance

M Anthony

B Somerville

Affiliations

Soon will be listed here.

Abstract

The effectiveness of five different serotonin antagonists in the prevention of migraine was compared in 290 patients followed for periods of up to three years. Methysergide 3-6 mg. daily was most effective, with 20% of treated patients becoming headache-free and a further 44% remaining more than "half improved." The corresponding figures for BC105 were 10% and 40%, respectively.The results with BC105 were significantly better than those with placebo (P<0.02). The total improvement rates with methdilazine (45%) and cyproheptadine (43%) were better than those with placebo (32%) but did not achieve statistical significance. A new preparation, methylergol carbamide maleate, which is chemically related to methysergide, did not give better results than placebo.

Citing Articles

Exploring the Tryptophan Metabolic Pathways in Migraine-Related Mechanisms.

Kortesi T, Spekker E, Vecsei L Cells. 2022; 11(23).

PMID: 36497053 PMC: 9736455. DOI: 10.3390/cells11233795.

Histamine and migraine revisited: mechanisms and possible drug targets.

Worm J, Falkenberg K, Olesen J J Headache Pain. 2019; 20(1):30.

PMID: 30909864 PMC: 6734463. DOI: 10.1186/s10194-019-0984-1.

Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Dib M Ther Clin Risk Manag. 2009; 4(5):1061-78.

PMID: 19209286 PMC: 2621398. DOI: 10.2147/tcrm.s3983.

Influence of pizotifen and ergotamine on the venoconstrictor effect of 5-hydroxytryptamine and noradrenaline in man.

Aellig W Eur J Clin Pharmacol. 1983; 25(6):759-62.

PMID: 6662174 DOI: 10.1007/BF00542515.

An assessment of platelet aggregation induced by 5-hydroxytryptamine.

Hilton B, Cumings J J Clin Pathol. 1971; 24(3):250-8.

PMID: 5573439 PMC: 476964. DOI: 10.1136/jcp.24.3.250.

References

CURRAN D, Hinterberger H, Lance J . Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain. 1965; 88(5):997-1010. DOI: 10.1093/brain/88.5.997. View

FEHER P, KALZ F . Studies in vascular permeability of human skin bradykinin. Dermatologica. 1966; 133(3):190-204. DOI: 10.1159/000254328. View

BIANCHINE J, Eade N . The effect of 5-hydroxytryptamine on the cotton pellet local inflammatory response in the rat. J Exp Med. 1967; 125(3):501-10. PMC: 2138287. DOI: 10.1084/jem.125.3.501. View

SICUTERI F, Franchi G, Del Bianco P . An antaminic drug, BC 105, in the prophylaxis of migraine. Pharmacological, clinical, and therapeutic experiences. Int Arch Allergy Appl Immunol. 1967; 31(1):78-93. DOI: 10.1159/000229856. View

Anthony M, Hinterberger H, Lance J . Plasma serotonin in migraine and stress. Arch Neurol. 1967; 16(5):544-52. DOI: 10.1001/archneur.1967.00470230096013. View

Lance J, Anthony M, GONSKI A . Serotonin, the carotid body, and cranial vessels in migraine. Arch Neurol. 1967; 16(5):553-8. DOI: 10.1001/archneur.1967.00470230105014. View

Lance J, Anthony M . Clinical trial of a new serotonin antagonist, BC105, in the prevention of migraine. Med J Aust. 1968; 1(2):54-5. DOI: 10.5694/j.1326-5377.1968.tb27464.x. View

Anthony M, Lance J . Indomethacin in migraine. Med J Aust. 1968; 1(2):56-7. DOI: 10.5694/j.1326-5377.1968.tb27465.x. View

RYAN R . Double-blind crossover comparison of bc-105, methysergide and placebo in the prophylaxis of migraine headache. Headache. 1968; 8(3):118-26. DOI: 10.1111/j.1526-4610.1968.hed0803118.x. View

10.

Dalessio D, CAMP W, GOODELL H, Wolff H . Studies on headache. The mode of action of UML-491 and its relevance to the nature of vascular headache of the migraine type. Arch Neurol. 1961; 4:235-40. DOI: 10.1001/archneur.1961.00450090001001. View

11.

Miller J, Fishman A . A serotonin antagonist in the treatment of allergic and allied disorders. Ann Allergy. 1961; 19:164-71. View

12.

CURRAN D, Lance J . CLINICAL TRIAL OF METHYSERGIDE AND OTHER PREPARATIONS IN THE MANAGEMENT OF MIGRAINE. J Neurol Neurosurg Psychiatry. 1964; 27:463-9. PMC: 495777. DOI: 10.1136/jnnp.27.5.463. View

13.

SICUTERI F . Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine. Int Arch Allergy Appl Immunol. 1959; 15:300-7. DOI: 10.1159/000229055. View